Seraticin

Seraticin is a novel antibiotic developed by scientists at Swansea University able to inhibit 12 different strains of MRSA, as well as E. coli and C. difficile. The research was funded by leading charity Action Medical Research, with support from the Rosetrees Trust. Seraticin was isolated as a compound of less than 500Da molecular weight from the maggot secretions of the common green bottle fly (Lucilia sericata).[1][2] It was patented in 2008 and has the empirical formula C
10H
16N
6O
9.[3]

References

  1. ↑ "Multi-Tasking Maggots In Superbug Showdown". ScienceDaily. 11 August 2012. Retrieved 8 December 2012.
  2. ↑ Bexfield A, Bond AE, Roberts EC, et al. (April 2008). "The antibacterial activity against MRSA strains and other bacteria of a <500Da fraction from maggot excretions/secretions of Lucilia sericata (Diptera: Calliphoridae)". Microbes Infect. 10 (4): 325–33. doi:10.1016/j.micinf.2007.12.011. PMID 18400544.
  3. ↑ "(WO2011042684) Antimicrobial Composition and a Method of Controlling Contamination and Infection Using Said Composition". US patent. 01.10.2010. Retrieved 8 December 2012. Check date values in: |date= (help)


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.